27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Of 285 participants randomized (suvorexant, N = 142; placebo, N = 143), 277 (97%) completed the trial (suvorexant, N = 136; placebo, N = 141). 4 key findings →
Participants: 142 Evidence: high
Full summary, score breakdown and related studies → Original source
In a large placebo-controlled randomized trial, we found that pantoprazole is not associated with any adverse event when used for 3 years, with the possible exception of an increased risk of enteric infections. 5 key findings →
Design: randomized controlled trial Participants: 8,791 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
ACHIEVE-P sets the stage for the full-scale ACHIEVE trial (N = 850, recruitment beginning November 2017), the first randomized trial to determine efficacy of a best practices hearing (vs. successful aging) intervention on reducing cognitive decline in older adults with HL. 1 key finding →
Design: randomized controlled trial Participants: 850 Evidence: high
Full summary, score breakdown and related studies → Original source
The mean rate of brain atrophy per year was 0.76% [95% CI, 0.63-0.90] in the active treatment group and 1.08% [0.94-1.22] in the placebo group (P = 0.001). 2 key findings →
Design: randomized controlled trial Participants: 271 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 267 (3.8%) women had diabetes and 297 (4.2%) had IFG. 3 key findings →
Design: randomized controlled trial Participants: 267 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD. 1 key finding →
Design: systematic review Participants: 44 Evidence: high
Full summary, score breakdown and related studies → Original source
A statistically significant age-adjusted association was observed between the A1C level and the score on all four cognitive tests. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
When completed in 2022, Aging and Cognitive Health Evaluation in Elders study should provide definitive evidence of the effect of hearing treatment versus education control on cognitive decline in community-dwelling older adults with mild-to-moderate hearing impairment. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
As none of the studies exceeded a duration of 6 months, the recommendations given are for the short-term management of the different non-motor symptoms. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Hearing loss is highly prevalent in dementia; however, people with dementia are less likely to use hearing aids consistently than people with intact cognition are. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
The of establishing the diagnosis of pneumonia and cause is with the antibiotic studies for of community-acquired studies for of community-acquired The diagnosis of is based on a of clinical and laboratory The diagnosis of is and and as well as disease, congestive heart failure, with pneumonia and cases of and are of do not require and are the of antibiotic antimicrobial is usually for and a chest radiography is usually to establish the diagnosis of examination to or is for detecting pneumonia Chest radiography is considered is for the etiologic the and or conditions. 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The mean plasma total homocysteine was 30% lower in those treated with B vitamins relative to placebo. 3 key findings →
Participants: 133 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
IER is as effective as CER with regard to weight loss, insulin sensitivity and other health biomarkers, and may be offered as an alternative equivalent to CER for weight loss and reducing disease risk. 1 key finding →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
OSA may aggravate cognitive dysfunction in dementia and thus may be a reversible cause of cognitive loss in patients with AD. 3 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
ABSTRACTBackground:Age-related hearing and vision problems are common among people with dementia and are associated with poorer function, reduced quality of life and increased caregiver burden. 3 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
There was a significant clustering of isolates from African compared with European patients, suggesting that the patients had acquired their isolates long before the development of clinical disease. 5 key findings →
Design: randomized controlled trial Participants: 54 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The Systolic Blood Pressure Intervention Trial will provide important information on the risks and benefits of intensive blood pressure treatment targets in a diverse sample of high-risk participants, including those with prior cardiovascular disease, chronic kidney disease, and those aged ≥75 years. 4 key findings →
Participants: 9,361 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
On average, participants were aged 63 years and had 16 years of education. 5 key findings →
Design: randomized controlled trial Participants: 100 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 110 participants (mean [SD] age, 67.9 [4.6] years; 68 female [61.8%]) were randomized to the experimental group (n = 55) and the sham group (n = 55) and included in the intention-to-treat analysis. 5 key findings →
Participants: 55 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Based on actigraphy as an objective measure of sleep time, melatonin is not an effective soporific agent in people with Alzheimer's disease. 3 key findings →
Participants: 157 Evidence: high
Full summary, score breakdown and related studies → Original source
ReDeSign provides dementia training to convenience store workers and contributes to developing an inclusive community for people with dementia. 1 key finding →
Design: randomized controlled trial Participants: 62 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Incentives are a cornerstone of attracting and retaining participants in clinical research studies.1 They serve as compensation for the time and effort individuals dedicate to the research process.1 However, previous randomized clinical trials found incentivizing was not associated with increased rates of clinical trial recruitment.2, 3 Furthermore, the rate participants redeem these incentives can vary considerably.1, 4 Although numerous methods have been used to increase trial recruitment, no studies have been conducted to explore factors associated with incentive redemption, regardless of clinical area. 5 key findings →
Design: cohort study Participants: 586 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Older adults with cognitive decline are vulnerable to various health problems. 2 key findings →
Design: randomized controlled trial Participants: 147 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Hypertension is a highly prevalent condition which has been established as a risk factor for cardiovascular and cerebrovascular disease. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
To investigate the response to an invitation to participate in a blended mobile Health intervention among adults living in deprived areas. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →